New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 29, 2014
07:48 EDTQ, CVD, AZN, PRXL, CRL, PFE, ICLRCROs sold off on unknowns from potential merger, says Jefferies
Jefferies attributes yesterday's sell-off in the Contract Research Organization space to the potential merger between Pfizer (PFE) and AstraZeneca (AZN) and the fear or other large pharma deals. The firm believes current share levels will prove attractive entry points over a three-year time frame. It notes Charles River Labs (CRL) and PAREXEL (PRXL) have the greatest exposure to the potential takeover of AstraZeneca while Covance (CVD) is less exposed. Other names in the CRO sector include ICON plc (ICLR) and Quintiles (Q).
News For CRL;CVD;ICLR;PRXL;Q;PFE;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
October 6, 2015
13:32 EDTAZN, PFEBiotechs plummet with TPP seen as industry negative
Biotechs are falling intraday after reports that the Trans-Pacific Partnership, or TPP, has language that the exclusivity period for bioligics, or drugs derived from a biological sources, would be eight years, less than the twelve years it is currently in the United States. WHAT'S NOTABLE: In the U.S., biologics are protected from competition by follow-on products for twelve years from the time they are first granted marketing approval by the U.S. Food and Drug Administration, a protection that is distinct from patent protection. Recent reports on the TPP suggest that the protection will last five years with an additional safety monitoring period of up to three years before a biosimilar can be registered, which would effectively be an eight year exclusivity period. ANALYST REACTION: Piper Jaffray analyst Joshua Schimmer, however, said the development is a "step forward," especially since it does not overrule the 12 years' exclusivity for the drugs in the U.S. While the sector asked for twelve years' exclusivity to match the U.S., eight years is a "reasonable compromise," the analyst argued. His top picks were Alexion (ALXN), Celgene (CELG), and Amgen (AMGN) in the large-cap space, GW Pharmaceuticals (GWPH) and bluebird bio (BLUE) among mid-caps, and Flex Pharma (FLKS), Lion Biotechnologies (LBIO), Otonomy (OTIC), and Ignyta (RXDX) in the small-cap sector. Further, Schimmer stated that more names look "increasingly compelling" amid the selloff. NOTABLE DECLINERS: Alexion is lower by 2.53%, Celgene is down 4.32%, Amgen is declining 1.91%, Biogen (BIIB) is down 3.4%, and Gilead Sciences (GILD) is falling 2.22%. STOCKS TO WATCH: Other publicly traded companies in the pharmaceutical space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07:23 EDTPFEAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 5, 2015
10:19 EDTPFESpark trial success a positive for gene therapy sector, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said he views the news that Spark Therapeutics (ONCE) "highly anticipated" SPK-RPE65 Phase 3 gene therapy study for congenital blindness met its primary endpoint as a positive for the ophthalmology gene therapy field as well as the broader gene therapy sector. Schimmer added that Applied Genetic Technologies' (AGTC) early clinical data in the second half of this year will be a further test of the ophthalmology gene therapy platform. The analyst noted that other companies with gene therapy programs include Avalanche (AAVL), Biogen (BIIB), bluebird bio (BLUE), BioMarin (BMRN), Cellectis (CLLS), Medgenics (MDGN), uniQure (QURE), Pfizer (PFE), Regeneron (REGN) and Sangamo (SGMO).
October 2, 2015
10:00 EDTPFEOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alexion (ALXN) upgraded to Overweight from Equal Weight at Morgan Stanley... BlackRock (BLK) upgraded to Buy from Neutral at UBS... Dunkin' Brands (DNKN) upgraded to Outperform from Underperform at CLSA... EnPro (NPO) upgraded to Buy from Neutral at Sidoti... Finish Line (FINL) upgraded to Neutral from Sell at Goldman... FutureFuel (FF) upgraded to Buy from Neutral at Roth Capital... Google (GOOG) upgraded to Outperform from Perform at Oppenheimer... Johnson Controls (JCI) upgraded to Buy from Neutral at Nomura... Kennametal (KMT) upgraded to Neutral from Underperform at BofA/Merrill... Lufthansa (DLAKY) upgraded to Buy from Hold at HSBC... Martin Marietta (MLM) upgraded to Buy from Neutral at Longbow... Northern Trust (NTRS) upgraded to Neutral from Sell at UBS... PMC-Sierra (PMCS) upgraded to Positive from Neutral at Susquehanna... Pfizer (PFE) upgraded to Overweight from Equal Weight at Morgan Stanley... Realogy (RLGY) upgraded to Buy from Neutral at Citi... Sarepta (SRPT) upgraded to Outperform from Neutral at Wedbush... Summit Materials (SUM) upgraded to Buy from Neutral at Goldman... TreeHouse (THS) upgraded to Buy from Neutral at BofA/Merrill... Vertex (VRTX) upgraded to Overweight from Equal Weight at Morgan Stanley.
08:16 EDTPFEPfizer upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Pfizer to Overweight and raised its price target to $38 from $35. Analyst David Risinger expects revenue growth to turn positive in 2016 after years of declines and said Pfizer has a strong balance sheet to take advantage of weakness in the pharma and biotech sectors. Risinger sees share upside with limited downside risk as fundamentals improve and management takes advantage of its strong financial position.
October 1, 2015
08:04 EDTPFEPfizer completes acquisition of Nimerix, Mencevax from GSK
Pfizer (PFE) announced that it has completed the acquisition of GlaxoSmithKline's (GSK) quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax.
07:39 EDTPFEJPMorgan sees opportunities in pharma after pullback
Subscribe for More Information
07:31 EDTPFE, AZNLeerink to hold a roundtable
Subscribe for More Information
September 30, 2015
09:59 EDTPFEActive equity options trading on open
Subscribe for More Information
08:37 EDTPFEPfizer lowers FY15 reported EPS view to $1.29-$1.38 from $1.38-$1.47
Subscribe for More Information
08:32 EDTPFEPfizer raises FY15 adjusted EPS view to $2.04-$2.10 from $2.01-$2.07
Subscribe for More Information
08:02 EDTAZNAstraZeneca says SYMBICORT results published in journal
Subscribe for More Information
September 29, 2015
16:08 EDTPFELpath names Gary Atkinson as interim CEO
Lpath (LPTN) announced that Gary Atkinson has been appointed interim CEO of Lpath, effective immediately. Atkinson will continue to serve as Lpath's CFO. Atkinson joined Lpath as CFO in 2005, and has more than 20 years of experience with life science companies. Prior to Lpath, he served as the CFO for Quorex Pharmaceuticals, which was acquired by Pfizer (PFE).
16:00 EDTPFEOptions Update; September 29, 2015
Subscribe for More Information
14:20 EDTPFEPfizer's Wyeth to perform about $194M of cleanup work at Superfund site in NJ
Subscribe for More Information
08:07 EDTAZNAstraZeneca says Brilinta 60-mg tablets now available in U.S. pharmacies
Subscribe for More Information
September 28, 2015
15:01 EDTPFEPfizer volatility at high end of one-year range
Subscribe for More Information
07:52 EDTAZN, PFEIIR Holdings to hold a conference
Subscribe for More Information
07:27 EDTPFEFDA and the Parental Drug Association to co-host a conference
Subscribe for More Information
07:16 EDTQQuintiles shares likely to outperform, says Wells Fargo
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use